Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction
© Gan and Loh; licensee BioMed Central Ltd. 2010
Received: 18 March 2010
Accepted: 21 May 2010
Published: 21 May 2010
Drug resistance determination for Plasmodium falciparum infections are important to determining the type of treatment to be given. Besides in vivo experiments, molecular methods, such as sequencing and PCR, are now increasingly being used. Here a cheaper alternative to sequencing or the use of multiplex 5'nuclease PCR assay for detection and differentiation of drug resistance haplotypes for chloroquine and atovaquone using polymerase chain reaction-high resolution melt (PCR-HRM) is reported.
Separate PCR-HRM assays were designed for the detection and differentiation of chloroquine and atovaquone drug resistance haplotypes in P. falciparum. PCR was conducted on a thermal cycler and melt curves generated using a LightScanner. These were tested against reference strains of P. falciparum from MR4 as well as 53 local isolates.
The PCR-HRM assays are able to detect and differentiate between the various haplotypes consistently. These assays can also be used to detect new variants.
PCR-HRM is an inexpensive option for the determination of drug resistance profile in P. falciparum and will see increasing use as an alternative to sequencing and 5'nuclease PCR assays in reference laboratories or once PCR systems that are able to conduct HRM become commonplace.
The molecular basis of chloroquine resistance (CQR) in Plasmodium falciparum is still relatively unclear, and the association of point mutations in different genes with CQR has been largely studied in the last decade. In 2000, the pfcrt gene was identified, which appears to play a crucial role in CQR. A lysine to threonine change at position 76 (K76T), which was subsequently found in every in vitro CQR parasite from around the world, was identified as an important mutation associated with CQR . Although this mutation is not the sole requirement for determining of CQR, the absence of the K76T mutation is highly predictive of CQ sensitivity in vitro and CQ efficacy in vivo.
Similarly, the molecular basis of atovaquone resistance in P. falciparum has been suggested to be due to mutations in the cytochrome bc1 gene of the parasite mitochondrial genome, which prevents binding of atovaquone to the cytochrome . In particular, mutations at codon 268 are associated with atovaquone/proguanil treatment failure in vivo and can be used as possible resistance markers. Both the amino acid changes, Y268N and Y268S, result in extremely high increase in resistance levels . There are also recent reports of Y268C mutants that are also highly resistant to atovaquone .
One of the most common methods for single nucleotide polymorphism (SNP) detection is the conduct of a polymerase chain reaction (PCR) flanking the mutation site, followed by sequencing for confirmation . This process is however both laborious and expensive. Following the development of real-time PCR and relevant fluorescence detection systems, SNP detection became possible using fluorescent probe chemistries, such as the 5'nuclease PCR assay and fluorescent resonance energy transfer (FRET) PCR. These assays confer specificity while eliminating the need for confirmation via sequencing. Subsequently, PCR assays for the detection of chloroquine resistance based on these technologies were developed and widely used [7–9]. However, the use of fluorescent probes is limited to single SNP detection per probe and prior knowledge of the SNP location to design the detection probes. Thus, this method is relatively expensive especially in a multiplex PCR where several different fluorescent probes are required. In addition, there may be more SNPs at a particular locus than combination fluorescent probes that can be utilized. Hence, high resolution melting (HRM) analysis offers potential as a solution and here a PCR-HRM method for distinguishing between wild type and drug-resistant P. falciparum strains in a single reaction without the need for multiple fluorescent probes is presented.
The utility of HRM analysis for detection of point mutations in P. falciparum genes associated with drug resistance has been demonstrated earlier . The technique employed, however, is heavily reliant on the resolution power of the equipment as differences in melting temperature (Tm) between wild-type and mutant-type isolates are less than 2°C. Furthermore, as the size of the amplicon increases, the ability to detect small Tm difference decreases, thereby imposing a restriction on PCR primer design. Here, asymmetric PCRs were developed free from amplicon size restriction as the haplotype discrimination depends on a short (20 - 35 nucleotides), unlabeled 3'-blocked probe and LC Green Plus ® fluorescent dye. The assay is based on differences in melting temperature between perfect matches and mismatches under the probes and has been shown to be useful for SNP genotyping in genetic studies .
DNA from reference strains of P. falciparum (harbouring the known chloroquine resistance profiles) were provided by Malaria Research and Reference Reagent Resource Center (MR4) USA. These include MRA-152G, MRA-155G, MRA-156G, MRA-175G, MRA-202G and MRA-387G. DNA from these strains were used at a concentration of 1 pg/μl. Synthetic constructs were made for the atovaquone-resistant profile types Y268N and Y268S and were used at a concentration of 1 fmol/μl. A P. falciparum blood sample with atovaquone-resistant profile Y268C was obtained from Dr Colin Sutherland, London School of Hygiene and Tropical Medicine, UK. 53 other isolates of P. falciparum used in this study were part of a collection from DSO National Laboratories which were previously checked via PCR for mono-infection.
DNA was extracted from P. falciparum positive blood samples (parasitaemia greater than 0.05%) using the QIAamp DNA Mini Kit (Qiagen Inc). 200 μl of blood sample was used for extraction and DNA eluted in 100 μl of elution buffer.
PCR-HRM for the detection of chloroquine resistance
Primers used were previously described  and probes were designed using Primer 3 software . The PCR was set up in a final volume of 10 μl containing 1 μl of DNA, 75 nM of CRTD1 primer (5'-TGTGCTCATGTGTTTAAACTT-3'), 375 nM of CRTD2 primer (5'-CAAAACTATAGTTACCAATTTTG-3'), 500 nM of CRTWT probe (5'-TGTATGTGTAATGAATAAAATTTTTGC-phosphate-3'), 375 μM dNTP mix, 1× reaction buffer, 1× LC Green Plus (Idaho Technology Inc., USA), 6.875 mM MgCl2 and 0.5 U of Platinum Taq polymerase (Invitrogen Corp). After overlaying the PCR mix with 20 μl mineral oil, the following conditions were used: 95°C for 6 min; 60 cycles of 95°C for 15 s and 55°C for 1 min; followed by 94°C for 30 s and 25°C for 30 s for heteroduplex formation and 15°C for storage. This is followed by melt curve analysis on the LightScanner (Idaho Technology Inc., USA).
Real-time PCR for the detection of chloroquine resistance
The chloroquine resistance haplotypes for all P. falciparum isolates were determined using the multiplex real-time PCR assay developed by Sutherland et al.
PCR-HRM for the detection of atovaquone resistance
Primers and probes were designed using Primer 3 software. The PCR was set up in a final volume of 10 μl containing 1 μl of DNA, 50 nM of cytbF primer (5'-CACATCCTGATAATGCTATCG-3'), 250 nM of cytbR primer (5'-AGCTGGTTTACTTGGAACAG-3'), 500 nM of WT probe (5'-GGTACTTTCTACCATTTTATGCAATG-phosphate-3'), 100 μM dNTP mix, 1× reaction buffer, 1× LC Green Plus, 1.5 mM MgCl2 and 0.5 U of Platinum Taq polymerase. After overlaying the PCR mix with 20 μl mineral oil, the following conditions were used: 95°C for 6 min; 60 cycles of 94°C for 10 s, 55°C for 10 s and 72°C for 10 s; 72°C for 3 min, followed by 94°C for 30 s and 25°C for 30 s for heteroduplex formation and 15°C for storage. This is followed by melt curve analysis on the LightScanner (Idaho Technology Inc., USA).
PCR-RFLP for the detection of atovaquone resistance
The atovaquone resistance haplotypes for all P. falciparum isolates were determined using the PCR-RFLP method developed by Schwöbel et al.
Sensitivity of HRM assay in single and mixed strains reactions
In order to determine HRM assay sensitivity, serial dilutions of DNA (10-1 to 10-5 ng/μl) were tested. The pfcrt HRM assay was carried out on three different reference strains, MRA-102G (CVMNK haplotype), MRA-152G (SVMNT haplotype) and MRA-150G (CVIET haplotype) in duplicates. The same procedure was also performed on the atovaquone HRM assay but only with MRA-102G wild type reference strain.
The ability of the method to detect a minority haplotype in a mixture of wild- and mutant-type pfcrt alleles was also assessed. DNA concentration of both MRA-102G (CVMNK) and MRA-150G (CVIET) reference strains were adjusted to 0.1 ng/μl and combined to have the following CVMNK/CVIET ratio: 10:90, 30:70, 50:50, 70:30, 90:10.
Sanger's dideoxy sequencing was carried out on Exo-SAP purified PCR products using Big Dye Terminator v3.1 chemistry and electrophorezed on the Applied Biosystem 3730 Genetic Analyzer (Applied Biosystems, USA).
PCR-HRM for the detection of chloroquine resistance
PCR-HRM for the detection of atovaquone resistance
The PCR-HRM technique developed here is relatively inexpensive compared to the use of multiple fluorescent probes or sequencing . It provides a quick way to differentiate between drug-resistant strains and drug-sensitive strains using only a single unlabeled probe in an asymmetric PCR followed by a melt curve which is easily done without further chemistries. This technique is an improvement on the assay developed by Andriantsoanirina et al, as the use of the unlabeled probe allows for very clear distinction between wild-type and mutant type strains. Difficulties may be encountered in determining the exact resistant haplotype due to the small difference in Tm if PCR conditions and reagents used are not optimal or there is a lack of controls for each haplotype in the run. However, determination of drug resistance on a qualitative scale (i.e. sensitive or drug resistant) is relatively easy with this assay due to the larger Tm differences between wild type (sensitive) haplotype and resistant haplotypes.
Its ease of use is especially observed for detection of atovaquone resistance where alternatives currently available are sequencing and PCR-RFLP . Development of a multiplex 5'nuclease PCR assay to differentiate between the four haplotypes is not impossible but will likely require the use of multiple Lock-nucleic acid (LNA) or Minor grove binding (MGB) fluorescent-tagged probes which adds to the cost of the assay.
In addition, the use of HRM allows for the detection of new variants from the wild type, which could potentially be drug-resistant as well. It is predicted that the PCR-HRM method developed for pfcrt will be useful for the detection and differentiation of CVMNT, CVIKT and SVIET haplotypes discovered in Papua New Guinea  from wild type as well. This is further exemplified in the detection of two P. falciparum strains harbouring a point mutation just upstream of the variable region in pfcrt gene and confirmed by sequencing. The importance of this mutation is not known but it would have gone unnoticed if only the 5'nuclease PCR assay was used for detection purposes.
In this study, two systems were used in combination (conventional thermal cycler and the LightScanner) to generate the required result. There are now systems in the market that can do PCR and HRM together such as the Roche Lightcycler 480, Applied Biosystems ABI 7500 Fast PCR system as well as the Qiagen Rotor-Gene 6000 and it is expected that as such systems become more commonplace, it will provide a better option for seamless operation. However this needs to be tested to ensure that the HRM is of sufficient resolution power and robust enough to differentiate between mutant haplotypes consistently.
Conflict of interests
The authors declare that they have no competing interests.
We would like to thank Mr Victor Koh Wee Hong of DSO National Laboratories for the use of his collection of Plasmodium falciparum isolates for the testing and validation work. We also thank Dr Colin Sutherland and Martina Burke from the London School of Hygiene and Tropical Medicine UK for providing us with samples of the P. falciparum isolate harbouring the Y268C mutation. This study was supported by the Ministry of Defence, Singapore.
- Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CJ, Coulibaly D: A molecular marker for chloroquine resistant falciparum malaria. N Engl J Med. 2001, 344: 257-263. 10.1056/NEJM200101253440403.View ArticlePubMedGoogle Scholar
- Wellems TE, Plowe CV: Chloroquine-resistant malaria. J Infect Dis. 2001, 184: 770-776. 10.1086/322858.View ArticlePubMedGoogle Scholar
- Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q: Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000, 44: 2100-2108. 10.1128/AAC.44.8.2100-2108.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Schwöbel B, Alifrangis M, Salanti A, Jelinek T: Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J. 2003, 2: 5-10.1186/1475-2875-2-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Sutherland CJ, Laundy M, Price N, Burke M, Fivelman QL, Pasvol G, Klein JL, Chiodini PL: Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar J. 2008, 7: 240-10.1186/1475-2875-7-240.PubMed CentralView ArticlePubMedGoogle Scholar
- Kwok PY: Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet. 2001, 2: 235-258. 10.1146/annurev.genom.2.1.235.View ArticlePubMedGoogle Scholar
- Farcas GA, Soeller R, Zhong K, Zahirieh A, Kain K: Real-time polymerase chain reaction assay for the rapid detection and characterization of chloroquine-resistant Plasmodium falciparum malaria in returned travellers. Clin Infect Dis. 2006, 42: 622-627. 10.1086/500134.View ArticlePubMedGoogle Scholar
- Sutherland CJ, Haustein T, Gadalla N, Armstrong M, Doherty JF, Chiodini PL: Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrob Agents Chemother. 2007, 59: 1197-1199. 10.1093/jac/dkm104.View ArticleGoogle Scholar
- Keen J, Farcas GA, Zhong K, Yohanna S, Dunne MW, Kain KC: Real-time PCR assay for rapid detection and analysis of pfcrt haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India. J Clin Microbiol. 2007, 45: 2889-2893. 10.1128/JCM.02291-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Andriantsoanirina V, Lascombes V, Ratsimbasoa A, Bouchier C, Hoffman J, Tichit M, Rabarijaona LP, Durand R, Ménard D: Rapid detection of point mutations in Plasmodium falciparum genes associated with antimalarial drugs resistance by using High-Resolution Melting analysis. J Microbiol Methods. 2009, 78: 165-170. 10.1016/j.mimet.2009.05.013.View ArticlePubMedGoogle Scholar
- Yan JB, Xu HP, Xiong C, Ren ZR, Tian GL, Zeng F, Huang SZ: Rapid and Reliable Detection of Glucose-6-Phosphate Dehydrogenase Gene Mutations in Han Chinese Using High-Resolution Melting Analysis. J Mol Diagn. 2010, 12: 305-311. 10.2353/jmoldx.2010.090104.PubMed CentralView ArticlePubMedGoogle Scholar
- Rozen S, Skaletsky HJ: Primer3. 1998, [http://www-genome.wi.mit.edu/genome_software/other/primer3.html]Google Scholar
- Vossen RHAM, Aten E, Roos A, den Dunnen T: High-resolution melting analysis (HRMA)-more than just sequence variant screening. Human Mutation. 2009, 30: 860-866. 10.1002/humu.21019.View ArticlePubMedGoogle Scholar
- Nagesha HS, Casey GJ, Rieckmann KH, Fryauff DJ, Laksana BS, Reeder JC, Maguire JD, Baird JK: New haplotypes of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene among chloroquine-resistant parasite isolates. Am J Trop Med Hyg. 2003, 68: 398-402.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.